CDSCO Modifies Norms For Testing Permissions To Speed Up Drug Approvals

The Central Drug Standard Control Organization (CDSCO) has revised its testing permission regulations to expedite the drug approval process in India. This change aims to streamline the mandatory testing phase, which is essential before any drug can receive approval for market entry. The testing is conducted at various government laboratories, including the Indian Pharmacopoeia Commission (IPC), Central Drugs Testing Laboratory in Mumbai, Central Drugs Laboratory at CRI Kasauli, and the National Institute of Biologicals in Noida. The modifications are expected to reduce bottlenecks in drug approvals, thereby enhancing access to essential medications for the Indian populace. This move aligns with the government's ongoing efforts to improve healthcare delivery and ensure timely availability of pharmaceuticals in the market, particularly in light of the recent challenges faced during the COVID-19 pandemic. By facilitating quicker approvals, the CDSCO aims to bolster the pharmaceutical sector and improve overall public health outcomes.